The Merck Access Program may be able to help answer questions related to insurance coverage and financial assistance options for certain Merck products including questions about:. The Merck Patient Assistance Program provides certain medicines and adult vaccines free of charge to eligible individuals who do not have insurance or whose insurance does not cover their prescription Merck products.
Find tips to support your health and wellness and get inspired by stories of people just like you. Private Securities Litigation Reform Act of There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.
If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
No Duty to Update The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments.
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. By continuing, you will be directed to a site intended only for residents of the United States and Canada. Skip to content.
A resource for your patients with type 2 diabetes to help with healthy eating and portion control. This resource provides an example of a balanced plate and information on food groups and serving sizes to help encourage healthy eating choices.
A resource for your Spanish-speaking patients with type 2 diabetes to help with healthy eating and portion control. This resource provides a culturally-relevant example of a balanced plate and information on food groups and serving sizes to help encourage healthy eating choices. A resource for your patients with type 2 diabetes to help with healthy eating and meal planning.
This resource provides information about carbs and meal planning with comparisons to help encourage healthy eating choices. Your eligible, privately insured patients can visit Januvia. This patient website provides product information and patient resources. Your eligible, privately insured patients who speak Spanish can visit Januvia. JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. An association between dipeptidyl peptidase-4 DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class.
These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. A dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis. When JANUVIA was used in combination with insulin or insulin secretagogues eg, sulfonylurea , medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo.
Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia. The incidence and rate of hypoglycemia based on all reports of symptomatic hypoglycemia were: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome.
Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.
Angioedema has also been reported with other DPP-4 inhibitors. There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors.
0コメント